Rash or remission? new study aims to decode drug side effect in rare skin cancers
NCT ID NCT07003100
First seen Jun 26, 2026 · Last updated Sep 15, 2026 · Updated 2 times
Summary
This study tracks 100 adults with mycosis fungoides or Sézary syndrome who are starting mogamulizumab, a standard treatment. The drug often causes a rash that can look like the cancer itself. Researchers want to help doctors tell the difference so they don't stop a working drug too soon. Participants will have skin biopsies and blood tests to study the rash.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- mogamulizumab
- What this could lead to
- If successful, this study could help doctors accurately identify mogamulizumab-associated rash, preventing unnecessary early stopping of a working treatment.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve outcomes. The rash may still be hard to distinguish from disease progression in some cases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2024
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients diagnosed with relapsed/refractory Mycosis Fungoides (MF) stage IB, IIA, IIB, III and IV or Sezary Syndrome(SS), and selected by their treating physician to receive single agent mogamulizumab (newly initiated).
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * \* Adult patients (\>= 18 years of age) diagnosed with relapsed/refractory Mycosis Fungoides (MF) stage IB, IIA, IIB, III and IV or Sezary Syndrome(SS), and selected by their treating physician to receive single agent mogamulizumab (newly initiated) * Signed informed consent * Willing to undergo baseline biopsy and during treatment to evaluate for Mogamulizumab-Associated Rash (MAR) if clinically indicated * Willing to provide blood sample at baseline, and if applicable, at onset of Mogamulizumab-Associated Rash (MAR) Exclusion Criteria: * \* Other concomitant systemic and skin directed Cutaneous T-cell Lymphoma (CTCL) regimens except for topical steroids * Prior treatment with mogamulizumab
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Recurrent mycosis fungoides are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
10 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Brigham and Women's Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02115, United States
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
-
Emory University Hospital/Winship Cancer Institute
NOT_YET_RECRUITINGAtlanta, Georgia, 30322, United States
-
Fred Hutchinson Cancer Center
NOT_YET_RECRUITINGSeattle, Washington, 98109, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
NOT_YET_RECRUITINGBaltimore, Maryland, 21287, United States
-
M D Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Moffitt Cancer Center
NOT_YET_RECRUITINGTampa, Florida, 33612, United States
-
Siteman Cancer Center at Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
-
Stanford Cancer Institute Palo Alto
NOT_YET_RECRUITINGPalo Alto, California, 94304, United States
-
Thomas Jefferson University Hospital
NOT_YET_RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Lower-Dose radiation 'Rotisserie' treatment ease skin lymphoma symptoms?
- New combo shows promise for rare blood cancer
- Two-Drug attack on tough lymphoma shows promise in early trial
- Experimental antibody takes aim at tough lymphoma
- Engineered virus targets Hard-to-Treat blood cancers in new trial
- New drug combo targets Hard-to-Treat skin cancers in early trial